COMPARATIVE IN-VITRO ACTIVITIES OF TROVAFLOXACIN (CP-99,219) AGAINST 445 GRAM-POSITIVE ISOLATES FROM PATIENTS WITH ENDOCARDITIS AND THOSE WITH OTHER BLOOD-STREAM INFECTIONS

The in vitro activity of trovafloxacin (CP-99,219), a new fluoroquinol one, was compared with the in vitro activities of other commonly used quinolones and other antimicrobial agents against 445 gram-positive mi croorganisms isolated between 1986 and 1995 from patients with endocar ditis and those with other blood- stream infections. The MICs at which 90% of the isolates are inhibited (MIC90) of trovafloxacin far methic illin-susceptible staphylococci, viridans group streptococci, and ente rococci were 0.06, 0.25, and 0.5 mg/liter, respectively. The MIC90 of trovafloxacin for vancomycin-resistant enterococci as well as for meth icillin-resistant Staphylococcus aureus and methicillin-susceptible an d ciprofloxacin-resistant S. aurcus, isolated from sources other than blood, was 1 mg/liter. For the quinolones the rank order of activity w as trovafloxacin > sparfloxacin > ciprofloxacin = ofloxacin > pefloxac in. Depending on the species tested, trovafloxacin was 4- to 64-fold m ore active than ciprofloxacin. Further experimental and in vivo studie s are warranted to evaluate the efficacy of trovafloxacin in the treat ment of bacterial endocarditis and other infections caused by gramposi tive organisms.